Frontiers in Oncology, 2022 BackgroundAdding metronomic capecitabine to concurrent chemoradiotherapy (CCRT) brings failure-free survival (FFS) benefits to patients with locoregionally advanced nasopharyngeal carcinoma (NPC).
Longjiang She +5 more
doaj +1 more source
Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review [PDF]
, 2018 Pancreatic cancer has a dismal prognosis particularly in patients presenting with unresectable tumors. We performed a bibliometric analysis of clinical trials for pancreatic cancer conducted between 2014-2016 focusing on patients that presented with ...
Biankin, Andrew V. +3 more
core +1 more source
Bevacizumab plus Irinotecan-Based Regimens in the Treatment of Metastatic Colorectal Cancer [PDF]
, 2010 Objectives: Bevacizumab is a monoclonal antibody that directly inhibits vascular endothelial growth factor, a key regulator of angiogenesis. Bevacizumab significantly improves progression-free and/or overall survival in metastatic colorectal cancer in ...
Heinemann, Volker, Hoff, Paulo M.
core +1 more source
Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patients. [PDF]
, 2020 Chemotherapy and checkpoint inhibitor immunotherapies are increasingly used in combinations. We determined associations between the presence of anti-PD-1/PD-L1 therapeutic biomarkers and protein markers of potential chemotherapy response.
Arguello, David +5 more
core +2 more sources
Adherence to prescribing restrictions for HER2-positive metastatic breast cancer in Australia: A national population-based observational study (2001-2016) [PDF]
, 2018 Background: Targeted cancer therapy is often complex, involving multiple agents and chemotherapeutic partners. In Australia, prescribing restrictions are put in place to reflect existing evidence of cost-effectiveness of these medicines.
Daniels, Benjamin +6 more
core +2 more sources
Frontiers in Endocrinology, 2022 Background and ObjectivePrevious studies determined the therapeutic effects of capecitabine-based chemotherapy regimens on early-stage triple-negative breast cancer (TNBC).
Zhiyang Li +11 more
doaj +1 more source
Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens. [PDF]
, 2014 PurposeWe sought to compare the economic impact of treatment-related adverse events (AEs) in patients with metastatic breast cancer (mBC) using taxane- or capecitabine-based treatment regimens as either first- or second-line (FL or SL) therapy in the US ...
Brammer, Melissa +7 more
core +1 more source
Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC) [PDF]
, 2013 Management of metastatic colorectal cancer requires a multimodal approach and must be performed by an experienced, multidisciplinary expert team. The optimal choice of the individual treatment modality, according to disease localization and extent, tumor
BASSO, ENRICO +15 more
core +1 more source
5-Fluorouracil degradation rate as a predictive biomarker of toxicity in breast cancer patients treated with capecitabine [PDF]
, 2020 Capecitabine is an oral prodrug of 5-fluorouracil with a relevant role in the treatment of breast cancer. Severe and unexpected toxicities related to capecitabine are not rare, and the identification of biomarkers is challenging.
Botticelli, A. +6 more
core +1 more source
BMC Cancer, 2021 Background The role of capecitabine in neoadjuvant and adjuvant chemotherapy for early-stage triple-negative breast cancer (TNBC) is highly controversial.
Xingfa Huo +7 more
doaj +1 more source